Severe asthma: anti-IgE or anti-IL-5?-Reference-Cited by-同舟云学术

Severe asthma: anti-IgE or anti-IL-5?

Published:2016-01 Issue:1 Volume:3 Page:31813
ISSN:2001-8525
Container-title:European Clinical Respiratory Journal
language:en
Short-container-title:European Clinical Respiratory Journal

Author:

Papathanassiou Evgenia¹,Loukides Stelios¹,Bakakos Petros²

Affiliation:

1. 2nd Department of Respiratory MedicineAttikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece

2. 1st Department of Respiratory Medicine‘Sotiria’ Hospital of Chest Diseases, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3402/ecrj.v3.31813

Reference73 articles.

1. A summary of the new GINA strategy: a roadmap to asthma control

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

3. Refractory asthma – beyond step 5, the role of new and emerging adjuvant therapies

4. Tailored therapy for severe asthma

5. Monoclonal Antibodies for the Management of Severe Asthma

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ablative Treatment of Inflammatory and Other Diseases With Monoclonal Antibodies (Mabs) or Janus Kinases (Nibs) Increases Risk for Infection;Infectious Diseases in Clinical Practice;2023-10-23

2. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study;Internal Medicine;2022-06-01

3. Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma;Clinical & Experimental Allergy;2022-04

4. Dupilumab and tezepelumab in severe refractory asthma: new opportunities;Therapeutic Advances in Chronic Disease;2022-01

5. Blockade of CCL2/CCR2 signaling pathway prevents inflammatory monocyte recruitment and attenuates OVA-Induced allergic asthma in mice;Immunology Letters;2019-10